title: Immune modulation by dendritic-cell-based cancer vaccines.
abstract: The interplay between host immunity and tumour cells has opened the possibility of targeting tumour cells by modulation of the human immune system. Cancer immunotherapy involves the treatment of a tumour by utilizing the recombinant human immune system components to target the pro-tumour microenvironment or by revitalizing the immune system with the ability to kill tumour cells by priming the immune cells with tumour antigens. In this review, current immunotherapy approaches to cancer with special focus on dendritic cell (DC)-based cancer vaccines are discussed. Some of the DC-based vaccines under clinical trials for various cancer types are highlighted. Establishing tumour immunity involves a plethora of immune components and pathways; hence, combining chemotherapy, radiation therapy and various arms of immunotherapy, after analysing the benefits of individual therapeutic agents, might be beneficial to the patient.
authors.affiliation: APAC Biotech Pvt Ltd, Gurgaon, India, chaitanya@apacbiotech.com.
authors.forename: Chaitanya
authors.initials: C
authors.lastname: Kumar
authors.forename: Sakshi
authors.initials: S
authors.lastname: Kohli
authors.forename: Poonamalle Parthasarathy
authors.initials: PP
authors.lastname: Bapsy
authors.forename: Ashok Kumar
authors.initials: AK
authors.lastname: Vaid
authors.forename: Minish
authors.initials: M
authors.lastname: Jain
authors.forename: Venkata Sathya Suresh
authors.initials: VS
authors.lastname: Attili
authors.forename: Bandana
authors.initials: B
authors.lastname: Sharan
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines; D064987:Cell- and Tissue-Based Therapy; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D056747:Immunomodulation; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines